Abstract
Enterobacter xiangfangensis
is a novel, multidrug-resistant pathogen belonging to the Enterobacter genus and has the ability to acquire resistance to multiple antibiotic classes. However, there is currently no registered
E. xiangfangensis
drug on the market that has been shown to be effective. Hence, there is an urgent need to identify novel therapeutic targets and effective treatments for
E. xiangfangensis
. In the current study, a bacterial pan genome analysis and subtractive proteomics approach was employed to the core proteomes of six strains of
E. xiangfangensis
using several bioinformatic tools, software, and servers. However, 2611 nonredundant proteins were predicted from the 21,720 core proteins of core proteome. Out of 2611 nonredundant proteins, 372 were obtained from Geptop2.0 as essential proteins. After the subtractive proteomics and subcellular localization analysis, only 133 proteins were found in cytoplasm. All cytoplasmic proteins were examined using BLASTp against the virulence factor database, which classifies 20 therapeutic targets as virulent. Out of these 20, 3 cytoplasmic proteins: ferric iron uptake transcriptional regulator (FUR), UDP-2,3diacylglucosamine diphosphatase (UDP), and lipid-A-disaccharide synthase (lpxB) were chosen as potential drug targets. These drug targets are important for bacterial survival, virulence, and growth and could be used as therapeutic targets. More than 2500 plant chemicals were used to molecularly dock these proteins. Furthermore, the lowest-binding energetic docked compounds were found. The top five hit compounds,
Adenine
,
Mollugin
,
Xanthohumol C
,
Sakuranetin,
and
Toosendanin
demonstrated optimum binding against all three target proteins. Furthermore, molecular dynamics simulations and MM/GBSA analyses validated the stability of ligand–protein complexes and revealed that these compounds could serve as potential
E. xiangfangensis
replication inhibitors. Consequently, this study marks a significant step forward in the creation of new and powerful drugs against
E. xiangfangensis
. Future studies should validate these targets experimentally to prove their function in
E. xiangfangensis
survival and virulence.